This product profile describes the features of Tianlong’s SARS-CoV-2 Nucleic Acid Detection and its application in the fast diagnosis of COVID-19.
Rapid and reliable screening for SARS-CoV-2 is vital when it comes to understanding viral spread and limiting the pandemic. Tianlong offers an integrated solution for diagnosing COVID-19 patients using SARS-CoV-2 Nucleic Acid Amplification Tests based on the PCR method.
Tianlong always keeps track of how the newest strain of COVID-19 evolves and offers new products specifically designed to target the newest strain. With high sensitivity and precision, Tianlong's SARS-CoV-2 Nucleic Acid Detection Kits can facilitate fast diagnosis and contribute to pandemic control and prevention.
SARS-CoV-2 Multiple Detection Kits combine multiple tests into one, which can increase laboratory efficiency significantly.
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.
Read more »
Moderna reveals new highly targeted COVID-19 vaccine mRNA-1283Moderna has developed a new and improved version of its COVID-19 vaccine. The unique formulation (mRNA-1283) reduces the vaccine's content from the full-length SARS-CoV-2 spike protein to a narrowly focused encoding of just two segments—the N-terminal domain (NTD) and the receptor binding domain (RBD).
Read more »
How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.
Read more »
Moderna reveals new highly targeted COVID-19 vaccine mRNA-1283Moderna has developed a new and improved version of its COVID-19 vaccine. The unique formulation (mRNA-1283) reduces the vaccine's content from the full-length SARS-CoV-2 spike protein to a narrowly focused encoding of just two segments—the N-terminal domain (NTD) and the receptor binding domain (RBD).
Read more »